Yonatan Machado
Senior Investment Director @ Samsung NEXT
Yonatan Machado is a Series C investor at Samsung NEXT focused on Health Care and Medical. Yonatan Machado - Senior Investment Director @ Samsung NEXT
- Total investments:
- 12
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Yonatan Machado invests in
Health CareMedicalSoftwareArtificial IntelligenceWellness
Stages Yonatan Machado invests in
Series CSeries BSeedSeries A
Countries Yonatan Machado invests in
IsraelUnited StatesUnited Kingdom
Investment Focus
Industry
- Health Care 5 (42%)
- Medical 3 (25%)
- Software 3 (25%)
- Artificial Intelligence 3 (25%)
- Wellness 2 (17%)
Stage
- Series C 5 (42%)
- Series B 4 (33%)
- Seed 1 (8%)
- Series A 1 (8%)
Country
- Israel 4 (33%)
- United States 4 (33%)
- United Kingdom 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sibel Health
|
Sibel Health develops a neonatal epidermal system designed for wireless vital signs monitoring. It develops soft, flexible sensors that are powered by advanced analytics, operated by best-in-class software, and integrated with the cloud-optimized for artificial intelligence and machine learning.The company was founded in 2018 and is headquarteredin Niles, Illinois. | $9M / Series C / Sep 30, 2025 | |
Huma
|
Huma is a global health technology company that provides a modular platform to support digital 'hospitals at home' across different disease areas. Its platform combines predictive algorithms, digital biomarkers, and real-world data to advance proactive, predictive care and research.The company was founded in 2011 and is headquartered inLondon, England. | $100M / Series C / May 11, 2021 | |
Big Health
|
Big Health is a digital therapeutics company that operates a digital healthcare portal to offer fully-automated and highly personalized digital therapeutics and behavioral programs for mental health issues. Its portal offers an online personalized medicine-care and prepares a sleep improvement program in consultation with medical professionals thatenable individuals to overcome their sleep-related disorders in an efficient manner. | $39M / Series B / Jun 18, 2020 | |
Nexar
|
Nexar's mission is to reduce the chance of collisions and to make the road safer for everyone. Like a school of fish or a flock of birds, we want to get every car on the road moving safely and smoothly together. Using a Nexar-powered dash cam, AI and inter-vehicle networking, Nexar makes every car a smart car and is building the world’sfirst safe driving network. | $52M / Series C / Apr 30, 2020 | |
Anodot
|
Anodot’s Autonomous Analytics platform leverages advanced machine learning techniques to constantly analyze and correlate every business parameter, providing real-time alerts and forecasts, in their context, lowering time to detection and resolution. Our leading-edge, patented technology is trusted by clients in industries ranging from eCommerce tofintech, adtech, telco, gaming and more. We have your back, so you’re free to play the offense and grow your business. | $35M / Series C / Apr 16, 2020 | |
Rezilion
|
Rezilion automatically secures the software you deliver to customers, making it easier than ever before for teams to detect, prioritize and remediate software vulnerabilities.Powered by core Dynamic SBOM technology and deployed agentlessy, Rezilion works across your stack, helping you to know what software is in your environment, what isvulnerable, and what is actually exploitable in runtime, so you can focus on what matters, remediate automatically, and free up more dev time to build.DISCOVER - Discover all software components in your environments, from Dev to Prod, on-prem and cloud, hosts, containers and IoT devices.AGGREGATE - Enrich and consolidate scan results from multiple tools in a single dashboard for a complete view of your software attack surface.PRIORITIZE - Filter out non exploitable vulnerabilities that are in software components that aren'y executed in runtime (an 85% reduction).REMEDIATE - Cluster vulnerabilities to eliminate multiple problems at once and automatically execute remediation work to save teams time. | $8M / Seed / Dec 10, 2019 | |
DayTwo
|
DayTwo is a precision nutrition company that uses food as medicine to enable a path to remission for metabolic diseases including diabetes, prediabetes, clinical obesity, and NAFLD. DayTwo's groundbreaking scientific discovery, published in CELL (2015) and JAMA (2019) determined that people respond differently to the same food, thus knowingwhat food “works” for each person is crucial to an effective care plan. DayTwo uses gut microbiome sequencing (stool sample, akin to Cologuard) to create Food Prescriptions™ for each patient which balance blood sugar levels, improve energy, manage hunger, and help members lose weight. DayTwo virtual care solution is delivered through Certified Diabetes Care and Education Specialists and Registered Dietitians using a digital app to track progress and communicate with members. | $5M / Series B / Oct 06, 2019 | |
Healthy.io
|
Healthy.io is a pioneer in turning the smartphone camera into a clinical grade medical device. Founded in 2013 by founder and CEO, Yonatan Adiri, it took us only three years to reach from idea to global revenues through successful clinical trials. Our first product, Dip.io, is the world’s first clinically approved home urinalysis kit. The producteffectively turns the smartphone into a clinical grade urinalysis device, enabling the layperson to conduct clinically required urine testing with a simple smartphone scan. Dip.io was followed by ACR - a second urinalysis test that lets people with diabetes or high blood pressure reliably test themselves at home for kidney disease. The product achieved 99% usability success and is being rolled out for large population screening in Europe, using digital technology to change the dynamics of chronic kidney disease prevention. Our second product family - Chronic wound monitoring - is an assessment tool to analyze chronic wounds over time and facilitate better care coordination. | $60M / Series C / Sep 11, 2019 | |
|
DayTwo
|
DayTwo is a precision nutrition company that uses food as medicine to enable a path to remission for metabolic diseases including diabetes, prediabetes, clinical obesity, and NAFLD. DayTwo's groundbreaking scientific discovery, published in CELL (2015) and JAMA (2019) determined that people respond differently to the same food, thus knowingwhat food “works” for each person is crucial to an effective care plan. DayTwo uses gut microbiome sequencing (stool sample, akin to Cologuard) to create Food Prescriptions™ for each patient which balance blood sugar levels, improve energy, manage hunger, and help members lose weight. DayTwo virtual care solution is delivered through Certified Diabetes Care and Education Specialists and Registered Dietitians using a digital app to track progress and communicate with members. | $31M / Series B / Jun 26, 2019 | |
|
Healthy.io
|
Healthy.io is a pioneer in turning the smartphone camera into a clinical grade medical device. Founded in 2013 by founder and CEO, Yonatan Adiri, it took us only three years to reach from idea to global revenues through successful clinical trials. Our first product, Dip.io, is the world’s first clinically approved home urinalysis kit. The producteffectively turns the smartphone into a clinical grade urinalysis device, enabling the layperson to conduct clinically required urine testing with a simple smartphone scan. Dip.io was followed by ACR - a second urinalysis test that lets people with diabetes or high blood pressure reliably test themselves at home for kidney disease. The product achieved 99% usability success and is being rolled out for large population screening in Europe, using digital technology to change the dynamics of chronic kidney disease prevention. Our second product family - Chronic wound monitoring - is an assessment tool to analyze chronic wounds over time and facilitate better care coordination. | $18M / Series B / Feb 05, 2019 | |
| See all 12 investments → | |||
Co-Investors
Aleph
4 deals together
Cathay Innovation
2 deals together
Corner Ventures
2 deals together
Intel Capital
2 deals together
La Maison Compagnie d'Investissement
2 deals together
Longliv Ventures
2 deals together
About Samsung NEXT
Samsung NEXT Ventures is an investment arm of Samsung NEXT, a multifaceted innovation group within Samsung Electronics dedicated to identifying new growth opportunities that will define the next decade. The firm prefers to invest in artificial intelligence, fintech, blockchain, health technology, infrastructure, and media technology sectors.
Samsung NEXT Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Carlos Castellanos
Venture Capitalist
|
|||
Nick Nigam
Principal, Seed to Series B Venture Capital Investments
|
|||
|
Yonatan Machado
Senior Investment Director
|
|||
Ajay Singh
Director
|
|||
Alicia Garabedian
Venture Operations Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Artificial intelligence Investors
40,702 investors
Medical Investors
18,848 investors
Wellness Investors
11,737 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Health Care VC Funds
32,370 investors
FAQ
What does Yonatan Machado invest in?
Yonatan Machado invests primarily in Health Care, Medical and Software startups, most often at Series C and Series B stage. Most of the 12 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Yonatan Machado last invest?
The most recent investment recorded for Yonatan Machado closed in Sep 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
